NRSN

Healthcare Biotechnology

NeuroSense Therapeutics Ltd.

$4.03

+0.28 +7.47% today

Price History

Not enough data

Key Stats

Market Cap

7.64M

Avg Volume

295,326

EPS

-$47.10

52W High

$26.64

52W Low

$3.82

Div. Yield

0.0%

Analyst Ratings

Buy

Str Buy

Buy

Hold

Sell

Str Sell

Valuation

Forward P/E

-0.34

P/B Ratio

-4.21

EV/EBITDA

-0.64

Margins

Gross Margin 0.0%

Operating Margin 0.0%

Net Margin 0.0%

EBITDA Margin 0.0%

Growth & Returns

Return on Equity

(2175.0%)

Return on Assets

(247.3%)

Liquidity & Leverage

Current Ratio

0.31

Quick Ratio

0.08

Total Cash

166,000

Total Debt

170,000

About

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.